Molecular mechanism and function of CD40/CD40L engagement in the immune system

Immunological Reviews - Tập 229 Số 1 - Trang 152-172 - 2009
Raúl Elgueta1, Micah J. Benson2, Victor C. de Vries2, Anna Wasiuk2, Yanxia Guo2, Randolph J. Noelle2
1Department of Microbiology and Immunology, Dartmouth Medical School and The Norris Cotton Cancer Center, Lebanon, NH 03756, USA
2Department of Microbiology and Immunology, Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH, USA

Tóm tắt

Summary:  During the generation of a successful adaptive immune response, multiple molecular signals are required. A primary signal is the binding of cognate antigen to an antigen receptor expressed by T and B lymphocytes. Multiple secondary signals involve the engagement of costimulatory molecules expressed by T and B lymphocytes with their respective ligands. Because of its essential role in immunity, one of the best characterized of the costimulatory molecules is the receptor CD40. This receptor, a member of the tumor necrosis factor receptor family, is expressed by B cells, professional antigen‐presenting cells, as well as non‐immune cells and tumors. CD40 binds its ligand CD40L, which is transiently expressed on T cells and other non‐immune cells under inflammatory conditions. A wide spectrum of molecular and cellular processes is regulated by CD40 engagement including the initiation and progression of cellular and humoral adaptive immunity. In this review, we describe the downstream signaling pathways initiated by CD40 and overview how CD40 engagement or antagonism modulates humoral and cellular immunity. Lastly, we discuss the role of CD40 as a target in harnessing anti‐tumor immunity. This review underscores the essential role CD40 plays in adaptive immunity.

Từ khóa


Tài liệu tham khảo

10.1073/pnas.96.1.185

10.1146/annurev.immunol.22.012703.104533

10.1038/ni737

10.1007/978-0-387-70630-6_3

10.1126/science.1496399

10.1002/jlb.67.1.2

10.1007/978-1-4615-1971-3_16

10.1126/science.1072615

10.1016/S0952-7915(97)80078-7

10.1002/eji.1830250639

10.1074/jbc.270.13.7025

10.1016/S0969-2126(01)00239-8

Carbone E, 1997, A new mechanism of NK cell cytotoxicity activation: the CD40‐CD40 ligand interaction, J Environ Monit, 185, 2053

10.1136/gut.2003.026278

10.1007/978-0-387-70630-6_11

10.1046/j.1600-6143.2003.00225.x

10.1016/S0041-1345(02)02907-X

10.1016/j.it.2004.03.008

10.1021/bi9909905

10.1021/bi981067q

10.1128/MCB.25.22.9806-9819.2005

10.1002/1521-4141(200201)32:1<39::AID-IMMU39>3.0.CO;2-Y

10.1074/jbc.M309601200

10.1182/blood-2006-07-038414

10.1073/pnas.96.15.8408

10.1002/1521-4141(2001010)31:10<3094::AID-IMMU3094>3.0.CO;2-F

10.1074/jbc.274.20.14246

10.1046/j.1365-2567.2001.01148.x

10.1074/jbc.274.27.19368

10.4049/jimmunol.165.9.5084

10.1084/jem.20020774

10.4049/jimmunol.176.9.5388

10.1074/jbc.M306708200

10.1016/S1074-7613(00)80390-8

10.1016/S1074-7613(00)80391-X

10.1038/ni1421

10.1016/j.cell.2007.10.037

10.1016/j.immuni.2008.01.009

10.1038/ni.1678

10.1038/ni.1676

10.1074/jbc.M111522200

10.1007/978-0-387-70630-6_4

10.1084/jem.20031255

10.1074/jbc.M205778200

10.1172/JCI200113620

10.1073/pnas.0500187102

10.1073/pnas.96.17.9803

10.4049/jimmunol.179.7.4645

10.1074/jbc.M100414200

10.1074/jbc.M303820200

10.4049/jimmunol.172.10.6047

10.1126/science.282.5392.1318

10.1016/S0092-8674(00)80405-5

10.4049/jimmunol.179.7.4473

10.1016/S1074-7613(00)80281-2

Revy P, 1999, Activation of the Janus kinase 3‐STAT5a pathway after CD40 triggering of human monocytes but not of resting B cells, J Immunol, 163, 787, 10.4049/jimmunol.163.2.787

10.1002/j.1460-2075.1994.tb06245.x

10.1146/annurev.iy.12.040194.004313

Barrett TB, 1991, CD40 signaling activates CD11a/CD18 (LFA‐1)‐mediated adhesion in B cells, J Immunol, 146, 1722, 10.4049/jimmunol.146.6.1722

10.1073/pnas.83.12.4494

10.1084/jem.172.6.1861

10.1006/smim.1994.1034

10.1084/jem.180.1.157

10.1084/jem.178.5.1567

10.1038/nri1334

10.1038/314537a0

10.1084/jem.160.4.1102

10.1038/340076a0

10.1073/pnas.84.15.5399

10.1073/pnas.81.19.6149

10.1073/pnas.82.8.2465

Bartlett WC, 1989, Cognate interactions between helper T cells and B cells. II. Dissection of cognate help by using a class II‐restricted, antigen‐specific, IL‐2‐dependent helper T cell clone, J Immunol, 143, 1745, 10.4049/jimmunol.143.6.1745

Bartlett WC, 1990, Cognate interactions between helper T cells and B cells. IV. Requirements for the expression of effector phase activity by helper T cells, J Immunol, 145, 3956, 10.4049/jimmunol.145.12.3956

10.1073/pnas.85.2.564

Hodgkin PD, 1990, Separation of events mediating B cell proliferation and Ig production by using T cell membranes and lymphokines, J Immunol, 145, 2025, 10.4049/jimmunol.145.7.2025

10.1073/pnas.89.14.6550

10.1038/357080a0

10.1016/j.immuni.2005.09.013

10.1016/j.immuni.2007.02.011

10.4049/jimmunol.161.3.1313

10.1084/jem.173.5.1165

10.1084/jem.176.3.679

10.1146/annurev.iy.12.040194.001001

10.1084/jem.178.5.1555

10.1126/science.281.5373.96

10.1016/1074-7613(94)90073-6

10.1016/j.coi.2007.04.009

10.4049/jimmunol.177.11.7723

10.1084/jem.20060087

10.1084/jem.20061254

10.1172/JCI0214110

10.1084/jem.192.11.1545

10.1146/annurev.immunol.26.021607.090344

10.1084/jem.192.11.1553

10.1084/jem.190.8.1123

10.1038/35018581

10.1084/jem.191.8.1303

10.1016/S0092-8674(00)81798-5

10.1038/35876

10.1084/jem.187.4.655

10.1002/j.1460-2075.1991.tb05011.x

10.1038/ni1100

10.1126/science.1136736

10.1084/jem.185.1.165

10.1084/jem.192.7.931

10.1093/intimm/8.5.737

10.1002/eji.1830230948

10.1038/342929a0

10.1084/jem.193.4.447

10.1182/blood.V88.4.1359.bloodjournal8841359

10.1084/jem.187.6.885

10.1038/ni792

10.1016/S1074-7613(02)00394-1

10.1093/intimm/14.3.319

10.1126/science.7533327

10.1073/pnas.96.4.1421

10.1006/smim.1994.1042

D’Orlando O, 2007, Outside inside signalling in CD40‐mediated B‐cell activation, J Biol Regul Homeost Agents, 21, 49

10.1097/MOT.0b013e328306115b

10.1158/1078-0432.CCR-06-1893

10.1080/08916930400002386

10.1126/science.1323143

10.1016/S1074-7613(94)80021-9

10.1097/00007890-199411270-00005

10.1084/jem.177.4.925

10.1006/cimm.1995.1031

10.4049/jimmunol.165.2.1111

10.1016/S0966-3274(01)00040-5

Honey K, 1999, CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression, J Immunol, 163, 4805, 10.4049/jimmunol.163.9.4805

10.1097/00007890-199811270-00021

10.1111/j.1600-6143.2007.01881.x

10.1136/thx.2005.047316

10.1097/00007890-199601150-00002

10.1073/pnas.92.21.9560

10.1182/blood-2003-02-0586

Wood ML, 1984, Comparison of immune responsiveness in mice after single or multiple donor‐specific transfusions, J Immunol, 132, 651, 10.4049/jimmunol.132.2.651

10.1016/S0041-1345(98)01588-7

10.1097/01.TP.0000093462.16309.73

10.1084/jem.20021215

Coulombe M, 1999, Tolerance to antigen‐presenting cell‐depleted islet allografts is CD4 T cell dependent, J Immunol, 162, 2503, 10.4049/jimmunol.162.5.2503

10.1038/32588

10.1097/00002371-200301000-00008

10.1016/S1074-7613(02)00272-8

10.1084/jem.186.12.2075

10.1038/15256

10.4049/jimmunol.166.4.2311

10.1038/15260

10.1385/IR:28:3:181

10.1097/01.TP.0000130449.05412.96

10.4049/jimmunol.179.12.8164

10.1084/jem.20070719

10.1073/pnas.0710441105

10.1172/JCI2703

10.1016/j.jaci.2008.01.002

10.1111/j.1399-3089.2007.00402.x

10.1097/01.tp.0000268074.77929.54

10.4049/jimmunol.176.3.1394

10.1097/01.TP.0000092525.17025.D0

10.1097/01.TP.0000173773.01811.88

10.4049/jimmunol.175.12.7855

10.4049/jimmunol.169.9.4831

10.2337/diabetes.54.2.443

10.1046/j.1600-6143.2003.00201.x

10.3346/jkms.2006.21.6.1005

10.1016/j.transproceed.2007.06.091

10.1111/j.1600-6143.2006.01550.x

10.4049/jimmunol.171.7.3878

10.1038/78621

10.1172/JCI8082

10.4049/jimmunol.165.12.6849

10.1038/ni1180

10.1038/ni846

10.4049/jimmunol.172.3.1691

10.1182/blood-2007-01-070748

10.1097/TP.0b013e3181726987

10.1111/j.1600-6143.2007.01886.x

10.1038/sj.onc.1208929

Bedian V, 2006, In vitro characterization and pre‐clinical pharmacokinetics of CP‐870,893, a human anti‐CD40 agonist antibody, J Clin Oncol, 24, 2539, 10.1200/jco.2006.24.18_suppl.2539

Bensinger W, 2006, A phase 1 dose escalation study of a fully human, antagonist anti‐CD40 antibody, HCD 122 (formerly CHIR‐12.12), in patients with relapsed and refractory multiple myeloma, Blood, 108, 3590, 10.1182/blood.V108.11.3575.3575

10.1038/nm1554

Byrd JC, 2006, Pharmacokinetics and pharmacodynamics from a first‐in‐human phase 1 dose escalation study with antagonist anti‐CD40 antibody, HCD 122 (formerly CHIR‐12.12) in patients with relapsed and refractory chronic lymphocytic leukemia, Blood, 108, 2837, 10.1182/blood.V108.11.2837.2837

10.1093/emboj/21.4.643

10.1002/ijc.2910430508

10.1002/(SICI)1096-9896(199905)188:1<38::AID-PATH315>3.0.CO;2-B

Altenburg A, 1999, CD40 ligand‐CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN‐gamma, J Immunol, 162, 4140, 10.4049/jimmunol.162.7.4140

10.1136/mp.55.2.110

Agathanggelou A, 1995, Expression of immune regulatory molecules in Epstein‐Barr virus‐associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells, Am J Pathol, 147, 1152

10.1172/JCI1472

Pellat‐Deceunynck C, 1996, CD11a‐CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation, Cancer Res, 56, 1909

Teoh G, 2000, CD40 activation mediates p53‐dependent cell cycle regulation in human multiple myeloma cell lines, Blood, 95, 1039, 10.1182/blood.V95.3.1039.003k02_1039_1046

10.1016/S0301-472X(02)00921-9

10.1002/eji.1830250533

10.1074/jbc.270.21.12343

10.1006/cimm.1996.0260

10.1073/pnas.96.16.9136

10.1016/S1074-7613(01)00258-8

10.1182/blood.V99.9.3411

10.4049/jimmunol.164.4.2200

10.1182/blood.V83.10.2787.2787

10.1023/A:1006012607452

10.1128/MCB.20.15.5503-5515.2000

Hess S, 1996, A novel function of CD40: induction of cell death in transformed cells, J Environ Monit, 183, 159

Eliopoulos AG, 1996, CD40‐induced growth inhibition in epithelial cells is mimicked by Epstein‐Barr virus‐encoded LMP1: involvement of TRAF3 as a common mediator, Oncogene, 13, 2243

Hirano A, 1991, Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand, Blood, 93, 2999, 10.1182/blood.V93.9.2999

Tong AW, 2001, Growth‐inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer, Clin Cancer Res, 7, 691

10.1038/sj.cgt.7700527

Mackey MF, 1997, Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154, Cancer Res, 57, 2569

10.1038/8426

10.1038/10495

10.1038/10503

10.1073/pnas.082107699

10.1073/pnas.191371898

10.1182/blood-2007-09-114371

10.1089/hum.1997.8.16-1935

Ribas A, 2001, CD40 cross‐linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene‐modified dendritic cells, Cancer Res, 61, 8787

10.1089/10430349950018049

10.1182/blood.V96.1.91

Forero‐Torres A, 2006, A humanized antibody against CD40 (SGN‐CD40) is well tolerated and active in non‐Hodgkin’s lymphoma (NHL): results of a phase 1 study, J Clin Oncol, 24, 7534, 10.1200/jco.2006.24.18_suppl.7534

10.1200/JCO.2001.19.13.3280

10.1200/JCO.2001.19.23.4351

10.1182/blood.V96.9.2917

Kipps TJ, 2000, Immunogenetic therapy for B‐cell malignancies, Semin Oncol, 27, 104

10.1046/j.1365-2141.2001.02760.x

10.1200/JCO.2006.08.3311

Hussein MA, 2005, A phase I humanized anti‐CD40 monoclonal antibody (SGN‐40) in patients with multiple myeloma, Blood, 106, 3576, 10.1182/blood.V106.11.2572.2572

10.1182/blood-2005-03-1259

10.1016/S0161-5890(00)00079-1

10.1182/blood-2007-04-084756

Nowak AK, 2003, Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors, Cancer Res, 63, 4490

10.1182/blood-2002-12-3717

Thông tin
Thông tin xuất bản

Immunological Reviews

Tập 229 Số 1

152-172

Thông tin tác giả